Management of anemia in patients with concurrent cancer and chronic kidney disease (CKD), as addressed by a position statement from the American Society of Onco-Nephrology (ASON).
The ASON issued consensus recommendations for diagnosing and treating anemia in the overlapping cancer-CKD population, addressing the complexity of multifactorial anemia in this group.
Position statements reflect expert consensus rather than primary trial data; recommendations may not be supported by high-quality randomized evidence specific to the cancer-CKD population.
Clinicians managing patients with both cancer and CKD should follow ASON guidance, which addresses the unique challenges of anemia in this overlap population where standard approaches for either condition alone may not apply.
